## Abstract No study has reported on the comparative effect of adefovir (ADV) addβon lamivudine (LAM) versus switching to entecavir (ETV) in LAMβresistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAMβresistant patients were enrolled (47 LAMβ+βADV and 45
β¦ LIBER β¦
Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine
β Scribed by Rifaat Safadi; Qing Xie; Yagang Chen; You-Kuan Yin; Lai Wei; Seong Gyu Hwang; Eli Zuckerman; Ji-Dong Jia; Patricia Lopez
- Book ID
- 111239396
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 202 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0106-9543
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Efficacy of adefovir add-on lamivudine r
β
Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu
π
Article
π
2010
π
John Wiley and Sons
π
English
β 134 KB
π 1 views
Efficacy of lamivudine therapy in elderl
β
Tomokazu Kawaoka; Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Yasuji Arase;
π
Article
π
2007
π
Springer Japan
π
English
β 202 KB
Lamivudine-to-entecavir switching treatm
β
Nao Kurashige; Kazuyoshi Ohkawa; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi M
π
Article
π
2009
π
Springer Japan
π
English
β 239 KB
Efficacy and safety of prolonged 3-year
β
Edward J. Gane; Yuming Wang; Yun-Fan Liaw; JinLin Hou; Satawat Thongsawat; MoBin
π
Article
π
2011
π
John Wiley and Sons
π
English
β 212 KB
Histological improvement in patients wit
β
Pieter Honkoop; Robert A. de Man; Pieter E. Zondervan; Solko W. Schalm
π
Article
π
2008
π
John Wiley and Sons
π
English
β 348 KB
Efficacy of entecavir in patients with c
β
Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C
π
Article
π
2009
π
John Wiley and Sons
π
English
β 287 KB
π 1 views
Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/